.svg)
FISABIO initiates a new study to develop a vaccine against Respiratory Syncytial Virus
- Office of the Principal
- September 30th, 2021
FISABIO is looking for people to participate in the research of a vaccine against respiratory syncytial virus in women aged 18 to 49 years old.
The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) has initiated a clinical trial in Valencia to study the new vaccine against respiratory syncytial virus in women aged 18 to 49 years old.
The respiratory syncytial virus (RSV) is a highly contagious virus which can affect everyone and, in mild cases, presents as a common cold. However, RSV can also cause more serious respiratory illnesses, mainly in older adults and young children.
If you would like to know more about the study to assess whether you are interested in participating in it, you can call the toll-free number 900 102 963 from Monday to Friday from 9 am to 2 pm.
YOUR PARTICIPATION CAN HELP MANY PEOPLE
File in: Grups de recerca , Investigació a la UV
Other News
Tags
Covid
Culture
Studies
Institutional
Organisation
People
Research, innovation and transfer
University and Society
Living at the University
